Kinetic Targeting of pegylated liposomal Doxorubicin: A new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Eckes, Jürgen ^a   Schmah, Oliver ^b   Siebers, Jan W ^c   Groh, Ursula ^c   Zschiedrich, Stefan ^b   Rautenberg, Beate ^b   Hasenburg, Annette ^b   Jansen, Martin ^b   Hug, Martin J ^b   Winkler, Karl ^b   Pütz, Gerhard ^b  

^a Medical Practice Cardiology and Angiology   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Hospital Offenburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; NAVELBINE; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MACROGOL DERIVATIVE; NANOPARTICLE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOUBLE FILTRATION PLASMAPHERESIS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TARGETING; ENDOMETRIUM CANCER; FATIGUE; HAND FOOT SYNDROME; HUMAN; KINETIC TARGETING; LEUKOPENIA; LIPOSOMAL DELIVERY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PLASMAPHERESIS; RASH; SIDE EFFECT; STOMATITIS; TUMOR VOLUME; BLOOD; BREAST TUMOR; DRUG TOXICITY; FEMALE; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BREAST NEOPLASMS; DOXORUBICIN; DRUG TOXICITY; FEMALE; HUMANS; MIDDLE AGED; NANOPARTICLES; OVARIAN NEOPLASMS; PLASMAPHERESIS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 79961113909     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-337     Document Type: Article

References (34)

1. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004, 303:1818-22. 10.1126/science.1095833, 15031496.
2. Gabizon A, Shmeeda H, Barenholz Y. Pharmakokinetics of Pegylated Liposomal Doxorubicin. Clin Pharmakokinet 2003, 42(5):419-36.
3. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors. Pharmacol Rev 1999, 51(4):692-743.
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
5. Northfelt DW, Martin FJ, Working P, Volberding PA, Russel J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmakokinetics, Tumor Localization, and Safety in Patients with AIDS-Related Kaposi Sarcoma. J Clin Pharmacol 1996, 36:55-63.
6. Amanthea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997, 61:301-11. 10.1016/S0009-9236(97)90162-4, 9084455.
7. Charrois GJR, Allen TM. Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmakokinetics and Therapeutic Activity. J Pharmacol Exp Ther 2003, 306(3):1058-67. 10.1124/jpet.103.053413, 12808004.
8. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes. Clin Cancer Res 2001, 7:243-254.
9. Putz G, Schmah O, Eckes J, Hug MJ, Winkler K. Controlled Application and scheduled Removal of Nanoparticle based Chemotherapeutics (CARL) will reduce Dose Limiting Adverse Events in Anticancer Chemotherapy. Med Hypotheses 2009, 72:393-7. 10.1016/j.mehy.2008.11.027, 19147297.
10. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment ofmetastatic breast cancer. Ann Oncol 2004, 15:440-9. 10.1093/annonc/mdh097, 14998846.
11. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007, 18:1159-64. 10.1093/annonc/mdl477, 17229768.
12. Lyass O, Uziely B, Ben-Yosef R, Tsemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma. Cancer 2000, 89:10-47.
13. Pütz G, Eckes J, Schmah O, Winkler K, Wieland H. Elimination of liposomes by different separation principles used in LDL-apheresis. Ther Apher 2008, 12(1):2-12.
14. Pütz G, Schmah O, Eckes J, Hug MJ, Winkler K. Controlled Application and Removal of Liposomal Therapeutics: Effective Elimination of Pegylated Liposomal Doxorubicin by Double-Filtration Plasmapheresis In Vitro. J Clin Apher 2010, 25(2):54-62. 10.1002/jca.20229, 20222030.
15. Bosch T. Therapeutic Apheresis-State of the Art in the Year 2005. Ther Apher 2005, 9(6):459-468.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-16. 10.1093/jnci/92.3.205, 10655437.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger A, Filbiberti H, Fletcher S, de Haes S, Klee D, Osoba D, Razavi B, Rofe S, Schraub K, Sneeuw M, Sullivan M, Takeda F. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
18. Klingel R, Fassbender T, Fassbender C, Goehlen B. From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low-density Lipoprotein Apheresis. Ther Apher Dial 2003, 7(3):350-358. 10.1046/j.1526-0968.2003.00062.x, 12924612.
19. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999, 10:1113-1116. 10.1023/A:1008323200102, 10572612.
20. Martin M, Garcia-Donas J, Casado A, de la Gandara I, Perez-Segura P, Garcia-Saenz JA, Ibanez G, Loboff B, Garcia-Ledo G, Moreno F, Grande E, Diaz-Rubio E. Phase II Study of Pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with previous Anthracycline Exposure. Clin Breast Canc 2004, 5(5):353-7.
21. Rose PG. Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer. The Oncologist 2005, 10:205-14. 10.1634/theoncologist.10-3-205, 15793224.
22. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with solid tumors. Canc Chemother Pharmacol 2008, 63(1):99-107.
23. Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS. A phase I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline. Canc Chemother Pharmacol 2008, 61:847-53.
24. Kotsakis A, Kouroussis C, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulias V, Mavroudis D. A dose escalating Study of pegylated liposomal doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors. Oncology 2006, 71:190-6. 10.1159/000106068, 17641537.
25. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL. Phase III Randomized Trial of Doxorubicin and Docetaxel versus Doxorubicin and Cyclophosphamide a s Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 2005, 23:2988-95. 10.1200/JCO.2005.06.156, 15860854.
26. García-Mata J, García-Palomo A, Calvo L, Mel R, ·Cruz JJ, ·Ramos M. Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. Clin Transl Oncol 2008, 10:739-744. 10.1007/s12094-008-0280-z, 19015070.
27. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B, Dieras V. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003, 14:1623-28. 10.1093/annonc/mdg449, 14581269.
28. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000, 78(3):369-372. 10.1006/gyno.2000.5921, 10985896.
29. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006, 24:2773-8. 10.1200/JCO.2005.03.8331, 16682726.
30. Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 2009, 117(3):591-8. 10.1007/s10549-008-0306-9, 19156515.
31. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II Study of Liposomal doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J Clin Oncol 1997, 15:987-93.
32. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models. J Drug Target 2002, 10(7):539-548. 10.1080/1061186021000072447, 12683721.
33. Grenader T, Gabizon A. What Is the Right Way to Administer Pegylated Liposomal Doxorubicin in Breast Cancer Therapy?. J Clin Oncol 2010, 28(12):e193-4. 10.1200/JCO.2009.26.8052, 20194839.
34. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-27. 10.1038/nrd2591, 20616808.